In this issue, Coronado et al. attempt to improve our understanding of the factors affecting the response to immunotherapy in a large subset of high-risk neuroblastoma with hemizygous deletion of chromosome 11q. By using several computational approaches, the authors study potential transcriptional and post-transcriptional pathways that may affect the response to immunotherapy and further be leveraged therapeutically in a biomarker-directed fashion.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858281 | PMC |
http://dx.doi.org/10.1002/1878-0261.12880 | DOI Listing |
Genes Genomics
January 2025
Department of Pediatric Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, Henan, China.
Background: The clinical course of high-risk neuroblastoma patients remains suboptimal, and the dynamic and reversible nature of cellular senescence provides an opportunity to develop new therapies.
Objective: This study aims to identify unique markers of cellular senescence in neuroblastoma and to explore their clinical significance.
Methods: The impact of multiple genetic regulatory mechanisms on cellular senescence-associated genes (CSAGs) was first assessed.
Clin Nucl Med
January 2025
From the Department of Nuclear Medicine, Beijing Friendship Hospital of Capital Medical University, Beijing, China.
An 8-year-old girl with refractory high-risk neuroblastoma underwent 68Ga-DOTATATE PET/CT to evaluate the feasibility of potential 177Lu-DOTATATE therapy. The scan showed multiple foci of abnormal 68Ga-DOTATATE accumulation in the bone region, indicating the presence of bone metastases. Unexpectedly, an abnormal tracer uptake was noted in the left lateral ventricle area.
View Article and Find Full Text PDFPediatr Blood Cancer
January 2025
Division of Hematology/Oncology and BMT, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio, USA.
Background: Neuroblastoma is the most common extracranial solid tumor in children, with about half of cases classified as high risk. Treatment varies by risk level, with high-risk patients undergoing aggressive multimodal therapy. While long-term survival has improved, survivors face significant risks of late treatment effects, including adrenal insufficiency.
View Article and Find Full Text PDFCurr Med Chem
January 2025
Healthy Ageing Research Centre, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Neuroblastoma (NB) is a rare embryonal neuroendocrine tumor that primarily affects children aged 5 years old or younger. In advanced stages, NB requires a multifaceted treatment approach, including a combination of surgery, chemo, and radiation therapy. However, high-risk NB is still associated with poor prognosis, long-term side effects, and a high chance of relapse.
View Article and Find Full Text PDFCancer Control
January 2025
Department of Radiology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, Chongqing, China.
Background: This study compared anatomical imaging features between high-risk and non-high-risk groups in neuroblastoma with at least one image-defined risk factor (IDRF). It also assessed the diagnostic performance of these features in identifying the high-risk group.
Methods: A retrospective analysis of neuroblastoma patients with at least one IDRF was conducted.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!